Shopping Cart
- Remove All
 
Your shopping cart is currently empty
YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1].

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 
| Description | YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1].  | 
| In vitro | YIAD-0205, at concentrations of 10 and 100 μM, inhibits the aggregation of Aβ (1-42) [1].  | 
| In vivo | YIAD-0205 (50 mg/kg; oral administration; biweekly for one month) was effective in reducing levels of Aβ plaques and Aβ oligomers in the 5XFAD mouse model aged at 6.0 months [1].  | 
| Molecular Weight | 565.69 | 
| Formula | C26H16Br2ClN3 | 
| Cas No. | 2446054-34-6 | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.